-
New gh Coming
Teva to sell Savient growth hormone deficiency treatment
TEV-TROPIN will be sold in the US through Teva subsidiary GATE Pharmaceuticals.
Globes correspondent 13 Feb 05 11:07
On Friday, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced that it would start selling and Savient Pharmaceuticals' (Nasdaq: SVNT) treatment for growth hormone deficiency TEV-TROPIN(TM) (somatropin for injection) in the US. Sales will be through Teva's wholly owned subsidiary GATE Pharmaceuticals
The product has been clinically tested and FDA-approved for growth hormone deficiency, and is manufactured by Savient using recombinant DNA (rDNA) technology.
The companies provided no revenue projections for the drug. In the third quarter of 2004, the last quarter on which it has reported, Savient lost $4.4 million on revenue of $4.26 million.
Published by Globes [online], Israel business news - www.globes.co.il - on February 13, 2005
-
interesting, is it injectable?
JohnnyB
-
